US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Executive Summary
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
You may also be interested in...
Trump's Budget Request To Include ANDA Exclusivity Changes
180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.
Trump's Budget Request To Include ANDA Exclusivity Changes
180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.
Generic Exclusivity Suit Says US FDA Can’t Deny Prize If It Asks For Extra Data
Amneal’s Namenda XR lawsuit asserts FDA’s determination that it forfeited 180-day marketing exclusivity on memantine extended-release generics ignores delays resulting from agency’s unexpected request for data from commercial-size lots.